Travere Therapeutics in the NEWS
Yesterday, Feb. 15, 2024, Travere Therapeutics, Inc. (TVTX) reported its fourth quarter and full year 2023 financial results and provided a corporate update.
Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics said, “With ongoing growth in demand for FILSPARI in IgAN and the initiation of the pivotal Phase 3 program of pegtibatinase in classical . . .
This content is for paid subscribers.
Trick or Trade
February 16, 2024
